JP2007515429A - 障害を治療する方法 - Google Patents

障害を治療する方法 Download PDF

Info

Publication number
JP2007515429A
JP2007515429A JP2006545607A JP2006545607A JP2007515429A JP 2007515429 A JP2007515429 A JP 2007515429A JP 2006545607 A JP2006545607 A JP 2006545607A JP 2006545607 A JP2006545607 A JP 2006545607A JP 2007515429 A JP2007515429 A JP 2007515429A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
cycloalkenyl
heteroaryl
aminocarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006545607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007515429A5 (enExample
Inventor
アンドリュー ナッパー，
ピーター ディスティファノ，
ジェフリー ヒクソン，
トーマス マクドナグ，
ローリー カーティス，
Original Assignee
エリクシアー ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エリクシアー ファーマシューティカルズ， インコーポレイテッド filed Critical エリクシアー ファーマシューティカルズ， インコーポレイテッド
Publication of JP2007515429A publication Critical patent/JP2007515429A/ja
Publication of JP2007515429A5 publication Critical patent/JP2007515429A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
JP2006545607A 2003-12-19 2004-12-20 障害を治療する方法 Pending JP2007515429A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53094503P 2003-12-19 2003-12-19
PCT/US2004/043207 WO2005060711A2 (en) 2003-12-19 2004-12-20 Methods of treating a disorder

Publications (2)

Publication Number Publication Date
JP2007515429A true JP2007515429A (ja) 2007-06-14
JP2007515429A5 JP2007515429A5 (enExample) 2008-02-07

Family

ID=34710193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006545607A Pending JP2007515429A (ja) 2003-12-19 2004-12-20 障害を治療する方法

Country Status (6)

Country Link
US (1) US20050250794A1 (enExample)
EP (1) EP1694323A4 (enExample)
JP (1) JP2007515429A (enExample)
CA (1) CA2550091A1 (enExample)
MX (1) MXPA06007054A (enExample)
WO (1) WO2005060711A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010087107A1 (ja) * 2009-01-29 2010-08-05 北海道公立大学法人札幌医科大学 メラノーマの転移抑制剤

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
DK1701940T3 (da) * 2003-12-23 2008-09-08 Lundbeck & Co As H 2-(1H-indolylsulfanyl)-bensylaminderivater som SSRI
WO2005118561A1 (en) * 2004-05-27 2005-12-15 Ucb, S.A. Benzoxazolone derivatives, processes for preparing them and their uses
DK1753512T3 (da) 2004-05-28 2008-11-17 4Sc Ag Tetrahydropyridothiophener
US7517986B2 (en) 2004-06-04 2009-04-14 4Sc Ag Tetrahydropyridothiophenes for use in the treatment of cancer
CA2569623A1 (en) 2004-06-11 2005-12-22 Altana Pharma Ag Novel compounds and use of tetrahydropyridothiophenes
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
CA2579089A1 (en) * 2004-08-30 2006-03-09 Government Of The United States Of America As Represented By The Secreta Ry Department Of Health And Human Services Inhibition of viruses using rnase h inhibitors
JP2008529989A (ja) 2005-02-09 2008-08-07 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌のような増殖性の疾病の治療用のテトラヒドロピリドチオフェン
US7741488B2 (en) 2005-02-11 2010-06-22 4Sc Ag Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer
AU2006251169A1 (en) 2005-05-25 2006-11-30 4Sc Ag Tetrahydropyridothiophenes for use in the treatment of cancer
WO2006125813A2 (en) 2005-05-25 2006-11-30 Nycomed Gmbh Tetrahydropyridothiophenes for use in the treatment of cancer
US7629473B2 (en) * 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
US20080021063A1 (en) * 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
DK2069352T5 (en) 2006-08-02 2017-04-03 Cytokinetics Inc SPECIFIC CHEMICAL UNITS, COMPOSITIONS AND PROCEDURES
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
WO2008060400A2 (en) * 2006-11-15 2008-05-22 Sirtris Pharmaceuticals, Inc. Sirtuin polymorphisms and methods of use thereof
EP2139478A4 (en) * 2007-03-30 2010-05-05 Cytokinetics Inc CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
EP2152262A2 (en) * 2007-04-27 2010-02-17 UCB Pharma, S.A. New heterocyclic derivatives useful for the treatment of cns disorders
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
JP5099794B2 (ja) 2007-11-27 2012-12-19 アルデア バイオサイエンシーズ インク． 新規化合物、組成物、及び使用方法
US7998976B2 (en) * 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
JP2011510985A (ja) * 2008-02-04 2011-04-07 サイトキネティックス， インコーポレイテッド 特定の化学的実体、組成物および方法
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
EP2367563A4 (en) 2008-12-08 2012-12-19 Univ Northwestern PROCESS FOR HSF-1 MODULATION
WO2010098866A1 (en) * 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
SG176983A1 (en) 2009-07-08 2012-02-28 Dermira Canada Inc Tofa analogs useful in treating dermatological disorders or conditions
EP2993236A1 (en) * 2010-04-15 2016-03-09 Glaxosmithkline LLC Sirtuin activators and activation assays
WO2012119605A1 (en) * 2011-03-10 2012-09-13 Akar Yahya Ahmed Abdellhafeez Salem New disperse dye with potent anticancer activity
EP2731611B1 (en) 2011-07-13 2019-09-18 Cytokinetics, Inc. Combination therapie for als

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098290A2 (en) * 2000-06-19 2001-12-27 Pharmacia Italia S.P.A. Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2002030353A2 (en) * 2000-10-12 2002-04-18 Smithkline Beecham Corporation NF-λB INHIBITORS
JP2007507530A (ja) * 2003-10-03 2007-03-29 アンフォラ ディスカバリー コーポレーション Ａｔｐ利用酵素阻害活性を示すチオフェンベース化合物、組成物、およびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL138825A (en) * 2000-10-03 2006-06-11 Neurim Pharma 1991 Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
US20040005574A1 (en) * 2002-07-08 2004-01-08 Leonard Guarente SIR2 activity
SK16052003A3 (en) * 2001-06-07 2004-10-05 Hoffmann La Roche New indole derivatives with 5-HT6 receptor affinity
US7241743B2 (en) * 2001-06-15 2007-07-10 The Trustees Of Columbia University In The City Of New York Sir2α-based therapeutic and prophylactic methods
DE60203529T2 (de) * 2001-09-27 2006-03-16 F. Hoffmann-La Roche Ag Indolderivate als cox-ii-inhibitoren
CA2538759C (en) * 2003-09-12 2015-11-03 Elixir Pharmaceuticals, Inc. Substituted heterocyclic compounds as sirtuin inhitibitors
EP1715855A4 (en) * 2004-01-29 2010-06-16 Elixir Pharmaceuticals Inc ANTIVIRAL DRUGS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098290A2 (en) * 2000-06-19 2001-12-27 Pharmacia Italia S.P.A. Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2002030353A2 (en) * 2000-10-12 2002-04-18 Smithkline Beecham Corporation NF-λB INHIBITORS
JP2007507530A (ja) * 2003-10-03 2007-03-29 アンフォラ ディスカバリー コーポレーション Ａｔｐ利用酵素阻害活性を示すチオフェンベース化合物、組成物、およびその使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010087107A1 (ja) * 2009-01-29 2010-08-05 北海道公立大学法人札幌医科大学 メラノーマの転移抑制剤

Also Published As

Publication number Publication date
MXPA06007054A (es) 2007-04-17
CA2550091A1 (en) 2005-07-07
WO2005060711A2 (en) 2005-07-07
EP1694323A4 (en) 2009-05-13
EP1694323A2 (en) 2006-08-30
WO2005060711A3 (en) 2005-09-09
US20050250794A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
US8486990B2 (en) SirT inhibitors that bind to NAD
JP2007515429A (ja) 障害を治療する方法
JP4908215B2 (ja) 疾患の治療法
CN102702013B (zh) 核受体结合剂
US20080214800A1 (en) Sirt inhibitors that bind to nad
AU2002253181B2 (en) Use of selective COX-2 inhibitors for the treatment of urinary incontinence
CN101801401A (zh) 激酶蛋白质结合抑制剂
AU2002253181A1 (en) Use of selective COX-2 inhibitors for the treatment of urinary incontinence
EP3341362A1 (en) Compositions for app-selective bace inhibition and uses therfor
JP2000500490A (ja) 糖尿病治療用の４−ヒドロキシクマリン−３−カルボキシアミド
US9457016B2 (en) Methods for treating polycystic kidney disease
EP3958851B1 (en) Allosteric activators of the alpha ia-adrenergic receptor
JPWO2019031425A1 (ja) 運動ニューロン疾患治療剤
CN101035527A (zh) 治疗疾病的方法
WO2023193809A1 (zh) Sarm1抑制剂化合物、包含其的药物组合物及其制备方法和用途
CN119923380A (zh) N-取代苯烷基胺及其作为治疗剂的应用
HU209446B (en) Process for preparing pharmaceutical compositions containing n,n- -dibenzyl-aminobutiric acid and its derivatives as active agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20101222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110316

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110415

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110516

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110523

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110810